Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma

NCT03005639 is registered in ClinicalTrials.gov with Inova Health Care Services as lead sponsor.

NCT NCT03005639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03005639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma
Lead sponsor
Inova Health Care Services
Phase
Phase 2
Overall status
Withdrawn
Start date
June 1, 2017
Completion date
February 24, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iiib-c melanoma